1.55
+0.03(+1.97%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.52 |
| Day High | 1.6 |
| Day Low | 1.52 |
| 52-Week High | 1.82 |
| 52-Week Low | 0.81 |
| Volume | 318,069 |
| Average Volume | 296,387 |
| Market Cap | 82.14M |
| PE | -0.99 |
| EPS | -1.56 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 1.3 |
| Change | 0.03 |
If you invested $1000 in PMV Pharmaceuticals, Inc. (PMVP) since IPO date, it would be worth $41.32 as of August 18, 2025 at a share price of $1.55. Whereas If you bought $1000 worth of PMV Pharmaceuticals, Inc. (PMVP) shares 3 years ago, it would be worth $106.68 as of August 18, 2025 at a share price of $1.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 11, 2025 1:00 PM GMT
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 1:00 PM GMT
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; i
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
GlobeNewswire Inc.
Oct 23, 2024 12:00 PM GMT
Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and